• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Adaptimmune Ther ADR (NQ: ADAP )

    1.175 +0.025 (+2.17%)
    Streaming Delayed Price Updated: 3:39 PM EDT, Apr 30, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Adaptimmune Ther ADR

    < Previous 1 2 3 4 5 Next >
    12 Health Care Stocks Moving In Friday's After-Market Session
    Via Benzinga
    Strategic Collaboration between Adaptimmune and Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies Terminated
    Company remains focused on launching afami-cel later this year with a PDUFA date of August 4th and developing its broader... 
    Via Newsfile
    Results of Adaptimmune's SPEARHEAD-1 Trial with Afami-cel in Advanced Sarcomas Published in the Lancet
    Philadelphia, Pennsylvania and Oxford, United Kindgom--(Newsfile Corp. - March 27, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining... 
    Via Newsfile
    Smith & Wesson Brands Reports Upbeat Earnings, Joins America's Car-Mart, HCI Group And Other Big Stocks Moving Higher On Friday
    U.S. stocks were higher, with the Dow Jones index gaining more than 100 points on Friday. 
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Adaptimmune Therapeutics Earnings Preview
    Via Benzinga
    Analyst Expectations for Adaptimmune Therapeutics's Future
    Via Benzinga
    Why Marvell Technology Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
    Shares of Marvell Technology, Inc. (NASDAQ: MRVL) fell sharply during Friday’s session after the company reported fourth-quarter financial results and issued weak Q1 guidance. 
    Via Benzinga
    ADAP Stock Earnings: Adaptimmune Therapeutics Misses EPS, Misses Revenue for Q4 2023
    ADAP stock results show that Adaptimmune Therapeutics missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023. 
    Via InvestorPlace
    Adaptimmune Reports Q4/Full Year 2023 Financial Results and Business Updates
    U.S. FDA accepted BLA for afami-cel for the treatment of advanced synovial sarcoma with priority review and a PDUFA date... 
    Via Newsfile
    Topics Economy
    Exposures Product Safety Supply Chain
    Earnings Scheduled For March 6, 2024
    Companies Reporting Before The Bell • CTS (NYSE:CTS) is estimated to report quarterly earnings at $0.14 per share on revenue of $708.85 million. 
    Via Benzinga
    Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company's Sarcoma Franchise
    Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - February 27, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining... 
    Via Newsfile
    Adaptimmune to Report Q4 and Full Year 2023 Financial and Business Updates on Wednesday, March 6, 2024
    Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - February 21, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining... 
    Via Newsfile
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session
    Via Benzinga
    Adaptimmune Announces U.S. FDA Acceptance of Biologics License Application for Afami-cel for the Treatment of Advanced Synovial Sarcoma with Priority Review
    If approved, afami-cel will be the first engineered T-cell therapy for solid tumors and the first effective treatment option for... 
    Via Newsfile
    Exposures Product Safety
    12 Health Care Stocks Moving In Monday's After-Market Session
    Via Benzinga
    Adaptimmune Projects Sarcoma Franchise to Deliver US Peak Year Sales up to $400 Million - Presentation at JP Morgan Healthcare Conference
    Sarcoma franchise of afami-cel and lete-cel leverages same development and commercial footprint with US peak year sales projected to be... 
    Via Newsfile
    Exposures Product Safety
    12 Health Care Stocks Moving In Friday's After-Market Session
    Via Benzinga
    Adaptimmune Completes Submission of Rolling Biologics License Application (BLA) to U.S. FDA for Afami-cel for the Treatment of Advanced Synovial Sarcoma
    First BLA for an engineered T-cell therapy for solid tumors submitted to U.S. Food and Drug AdministrationAfami-cel data demonstrate better... 
    Via Newsfile
    Exposures Product Safety
    Adaptimmune Receives Transfer of IND for Lete-cel Program
    Interim analysis of pivotal IGNYTE-ESO trial demonstrates 40% response rate in people with synovial sarcoma or myxoid/ round cell liposarcoma... 
    Via Newsfile
    Adaptimmune Reports Third Quarter Financial Results and Business Update
    Afami-cel: overall survival for people with synovial sarcoma who received afami-cel is superior to historic controls (CTOS 2023); BLA submission... 
    Via Newsfile
    Adaptimmune Selects ADP-600 as Clinical Candidate for Best-in Class PRAME Strategy
    Candidate is 10x more sensitive to target peptide than competitor candidatesEntry into the clinic in 2024Selection of approaches from next-gen... 
    Via Newsfile
    Adaptimmune Reports Better Outcomes for People with Synovial Sarcoma who Received Afami-cel Compared to Historical Control
    ~39% of patients who received afami-cel in the pivotal SPEARHEAD-1 trial had clinical responses with a median duration of response... 
    Via Newsfile
    Adaptimmune Reports Positive Data with Lete-cel[1] from an Interim Analysis of the Pivotal IGNYTE-ESO Trial for People with Synovial Sarcoma or MRCLS
    40% (18/45) of people with synovial sarcoma or MRCLS and who have received ≥ 2 prior lines of therapy had... 
    Via Newsfile
    Adaptimmune to Report Q3 2023 Financial and Business Updates on Wednesday, November 8, 2023
    Philadelphia, Pennsylvania and Oxfordshire, United Kingdom--(Newsfile Corp. - October 25, 2023) - Adaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in... 
    Via Newsfile
    Next-Generation TCR T-cell Therapy (ADP-A2M4CD8) Demonstrates Strong Efficacy in a Broad Range of Solid Tumors; Adaptimmune Presents Data Update from its SURPASS trial at ESMO
    35% response rate in the ADP-A2M4CD8 monotherapy cohort with ~5 months median duration of response in heavily pre-treated patients across... 
    Via Newsfile
    Dr. Karen Chagin Joins Adaptimmune as Senior Vice President of Early-Stage Development
    Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - September 11, 2023) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, today announces... 
    Via Newsfile
    12 Health Care Stocks Moving In Friday's After-Market Session
    Via Benzinga
    12 Health Care Stocks Moving In Thursday's After-Market Session
    Via Benzinga
    Adaptimmune Reports Second Quarter Financial Results and Business Update
    Substantial progress on the afami-cel BLA including FDA agreement on plan for confirmatory evidence and favorable feedback on commercial T-cell... 
    Via Newsfile
    Exposures Product Safety
    Adaptimmune to Report Q2 2023 Financial and Business Updates on Wednesday, August 9, 2023
    Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - August 3, 2023) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader... 
    Via Newsfile
    < Previous 1 2 3 4 5 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.